FDA APPROVES MERCK’S KEYTRUDA® (PEMBROLIZUMAB) IN COMBINATION WITH CHEMOTHERAPY FOR PATIENTS WITH LOCALLY RECURRENT UNRESECTABLE OR METASTATIC TRIPLE‑NEGATIVE BREAST CANCER WHOSE TUMORS EXPRESS PD-L1 (CPS ≥10)
The U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). “Approximately 15-20% of patients with breast cancer are diagnosed with triple-negative breast cancer, which […]
